Fig. 2.

Effects of danavorexton chronic dosing in orexin/ataxin-3 narcoleptic mice. Danavorexton increased wakefulness and ameliorated cataplexy-like episodes in orexin/ataxin-3 mice during the active phase after both single and repeated administration. (A) Time schedule of drug administration in mice during the active phase. (B) Time course of wakefulness after vehicle or danavorexton administration in orexin/ataxin-3 mice on day 14. In orexin/ataxin-3 mice during the active phase on day 14 (n = 8), effects of single and repeated administration of danavorexton on: (C) wakefulness time, (D) number of wakefulness episodes, and (E) duration of wakefulness episode. (F) In orexin/ataxin-3 mice during the active phase on day 15 (n = 8), effects of single and repeated administration of danavorexton on cataplexy-like episodes. Mean ± SEM. ***P ≤ 0.001 (two-tailed Tukey’s test). n.s., not significant; ZT, zeitgeber time.